Intraoperative autotransfusion in hepatic resection for malignancy. Is it safe?

Arch Surg. 1993 Feb;128(2):206-11. doi: 10.1001/archsurg.1993.01420140083013.

Abstract

To evaluate whether intraoperative autologous transfusion increases the risk of hematogenous dissemination of tumor we reviewed the risk of lung metastasis as well as disease-free and long-term survival of patients who underwent resection of malignant hepatic neoplasms with this technique. A retrospective review of patients undergoing liver resection for malignant disease revealed 39 patients in whom intraoperative autologous transfusion was used. The 2-year actuarial survival in the patients in this series, as calculated with the Kaplan-Meier method, was predicted to be 75%. Two-year actuarial disease-free survival was predicted to be 28%, and the risk of developing lung metastasis at 3 years was estimated to be 40%. The predicted overall survival and risk of recurrence in this series compare favorably with published data for patients in whom intraoperative autologous transfusion was not used.

MeSH terms

  • Actuarial Analysis
  • Adenoma, Bile Duct / surgery
  • Adult
  • Aged
  • Blood Component Transfusion
  • Blood Loss, Surgical
  • Blood Transfusion, Autologous* / methods
  • Carcinoma / secondary
  • Carcinoma / surgery
  • Carcinoma, Hepatocellular / surgery
  • Cause of Death
  • Female
  • Follow-Up Studies
  • Hepatectomy* / methods
  • Humans
  • Intraoperative Care*
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Retrospective Studies
  • Surgical Wound Infection / etiology
  • Survival Rate